ArticleTranslational cancer research2022
Screening and verification of prognostic lncRNA markers related to immune infiltration in the metastasis of osteosarcoma.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We sought to screen and verify the long non-coding ribonucleic acids (lncRNAs) related to immune infiltration in metastatic osteosarcoma (OS). Methods: We downloaded the RNA-sequencing expression data from The Cancer Genome Atlas (TCGA) database as the training data set. We downloaded the GSE39055 data set from the National Center for Biotechnology Information, Gene Expression Omnibus as the validation data set. The least absolute shrinkage and selection operator (LASSO) regression algorithm was used to screen the optimized lncRNA combinations. Kaplan-Meier curves were used to evaluate the associations between the lncRNAs and actual prognosis. The independent survival prognosis clinical factors were obtained by univariate and multivariate Cox analyses. A nomogram was established to explore the correlation between survival rate and risk information. The Tumor IMmune Estimation Resource was applied to estimate the composition of 6 subtypes of immune infiltration cells. Results: In total, 1,398 lncRNAs and 14,631 messenger RNAs were screened from TCGA data set, and divided into the low and high immunity groups. The Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression data (ESTIMATE) scores differed significantly between the samples in the two groups. Additionally, 5 optimized lncRNA combinations were obtained using the LASSO algorithm. Risk factors including age, metastatic tumor, and risk-score (RS) were related to the prognosis of OS patients. The survival rates predicted by the nomogram model were consistent with the actual survival rates of OS patients. Finally, we found that RS was negatively correlated with the proportion of immune cells. Conclusions: In total, 5 feature lncRNAs were identified as novel biomarkers for OS. Next, a RS nomogram model was constructed based on the 5 identified lncRNAs. This model predicted the survival rates and prognoses of OS patients well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.